BOSTON, MA—Patients with significant symptomatic degenerative mitral regurgitation (MR) who had complex anatomy making them ineligible for inclusion in the CLASP IID trial can be treated safely and ...
SAN FRANCISCO, CA—For patients with symptomatic degenerative mitral regurgitation (DMR) and a prohibitive surgical risk, transcatheter edge-to-edge repair (TEER) with either of two approved devices ...
SAN FRANCISCO -- The Pascal device remained noninferior to MitraClip for prohibitive surgical risk patients with significant symptomatic degenerative mitral regurgitation (DMR) in full results from ...
SAN FRANCISCO, Oct. 26, 2023 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) announced one-year results from CLASP IID, the first randomized controlled trial that directly compares two ...
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcatheter valve repair system for transcatheter ...
The FDA has approved Edwards Lifesciences Corp's (NYSE: EW) PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) for degenerative mitral regurgitation (DMR).
BOSTON, Sept. 17, 2022 /PRNewswire/ -- Edwards Lifesciences Corporation (EW) announced results from CLASP IID, the first randomized controlled trial that directly compares two contemporary ...
BOSTON – September 17, 2022 – Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral ...
Nationwide, there was a downtrend in both intermediate-risk and high-risk surgical mitral valve repair (MVr) volumes at centers that adopted TEER for degenerative mitral regurgitation (MR). The median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results